2024
M135 Counselor Terminological Preferences for "Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment
Gazzola M, Beitel M, Buck K, Cammack K, Saeed G, Eggert K, Roehrich T, Madden L, Barry D. M135 Counselor Terminological Preferences for "Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment. Drug And Alcohol Dependence 2024, 260: 110415. DOI: 10.1016/j.drugalcdep.2023.110415.Peer-Reviewed Original ResearchS94 Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol
Madden L, Farnum S, Eggert K, Cannata E, Hermes G, DiMeola K, Hoffman K, Barry D. S94 Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol. Drug And Alcohol Dependence 2024, 260: 110205. DOI: 10.1016/j.drugalcdep.2023.110205.Peer-Reviewed Original ResearchPerceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment
Gazzola M, Oberleitner L, Hoffman K, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Thompson E, Zheng X, Barry D. Perceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment. Substance Use & Addiction Journal 2024, 45: 568-576. PMID: 38551080, DOI: 10.1177/29767342241238837.Peer-Reviewed Original ResearchCommunity corrections officersCommunity corrections systemCorrection systemCommunity correctionsTreatment facilitatorsOpioid use disorderCorrective experiencesMethadone treatmentSubstance use disorder careCommunity supervisionCorrectional officersQualitative studyCoercive treatmentIncarceration historyOutpatient methadone treatmentIncarcerationDemographic surveyQualitative research teamNegative experiencesNegative perceptionsCommunitySemistructured interviewsPositive perceptionsInterviewsParoleA Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment
Gazzola M, Carmichael I, Thompson E, Beitel M, Madden L, Saeed G, Hoffman K, Hammouri M, Hsaio C, Barry D. A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment. Journal Of Addiction Medicine 2024, 18: 262-268. PMID: 38446859, DOI: 10.1097/adm.0000000000001282.Peer-Reviewed Original ResearchBrain disease modelMethadone treatmentTreatment beliefsIllness modelAssociated with beliefsOpioid use disorderUse disorderOutpatient opioid treatment programAddiction modelTreatment programsOpioid treatment programsAddictionMethadoneMultivariate analysisScale agreementIllnessDisordersCounselingBrainBeliefsDisease modelsOpioidPatientsStatistical significanceMultivariate regression
2023
The impact of body image dissatisfaction on psychological distress and health‐related quality of life among patients in methadone treatment
Carr M, Mannes Z, Oberleitner L, Oberleitner D, Beitel M, Gazzola M, Madden L, Zheng X, Barry D. The impact of body image dissatisfaction on psychological distress and health‐related quality of life among patients in methadone treatment. American Journal On Addictions 2023, 32: 460-468. PMID: 37188650, PMCID: PMC10524388, DOI: 10.1111/ajad.13432.Peer-Reviewed Original ResearchConceptsBody mass indexMethadone maintenance treatmentBody image dissatisfactionAverage body mass indexNon-Hispanic white menPsychological distressLower physical HRQoLHealth-related qualityLong-term courseLower mental HRQoLHigh psychological distressMental HRQoL.Image dissatisfactionMMT patientsObese rangePhysical HRQoLMaintenance treatmentMass indexMental HRQOLMethadone treatmentNormal weightOverweight rangeHigher body image dissatisfactionMMT outcomesPatients
2022
What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
Gazzola MG, Maclean E, Beitel M, Carmichael ID, Cammack KM, Eggert KF, Roehrich T, Madden LM, Jegede O, Zheng X, Bergman E, Barry DT. What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. Journal Of General Internal Medicine 2022, 38: 653-660. PMID: 36163526, PMCID: PMC9971370, DOI: 10.1007/s11606-022-07813-w.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance use disordersMethadone treatmentUse disordersOutpatient methadone treatment programMethadone treatment programsPresenting problemPreferences of patientsTerminology preferencesSubstance-dependent personsCross-sectional surveyAdult patientsMean ageUnivariate analysisMain MeasuresParticipantsPatientsTreatment programKey ResultsWeSubstance abuseSubstance useDisordersSignificant differencesTreatmentDemographic differencesAddiction counselors
2020
Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment
Baldassarri SR, Beitel M, Zinchuk A, Redeker NS, Oberleitner DE, Oberleitner LMS, Carrasco D, Madden LM, Lipkind N, Fiellin DA, Bastian LA, Chen K, Yaggi HK, Barry DT. Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment. Sleep And Breathing 2020, 24: 1729-1737. PMID: 32556918, PMCID: PMC7680294, DOI: 10.1007/s11325-020-02123-z.Peer-Reviewed Original ResearchConceptsOpioid use disorderExcessive daytime sleepinessDaytime sleepinessSleep qualityChronic painExcessive daytimeUse disordersConclusionsPoor sleep qualityCurrent chronic painModifiable risk factorsImpaired sleep qualityMultivariable linear regression modelsBody mass indexPoor sleep qualityNon-significant associationMass indexMultivariable analysisPain interferenceRelated comorbiditiesMethadone treatmentClinical correlatesMean PSQIRisk factorsSleep disordersResultsNinety percent
2018
A randomized clinical trial of the Recovery Line among methadone treatment patients with ongoing illicit drug use
Moore BA, Buono FD, Lloyd DP, Printz DMB, Fiellin DA, Barry DT. A randomized clinical trial of the Recovery Line among methadone treatment patients with ongoing illicit drug use. Journal Of Substance Use And Addiction Treatment 2018, 97: 68-74. PMID: 30577901, PMCID: PMC6310054, DOI: 10.1016/j.jsat.2018.11.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitive Behavioral TherapyCombined Modality TherapyFemaleHumansIllicit DrugsMaleMethadoneMiddle AgedNarcoticsOpiate Substitution TreatmentOutcome and Process Assessment, Health CareSelf ReportSelf-Help GroupsSelf-ManagementSubstance Abuse DetectionSubstance-Related DisordersTelephoneConceptsMethadone treatment patientsIllicit drug useDrug useTreatment patientsUrine screensOngoing illicit drug useDrug abstinencePrevious small trialsClinical efficacy trialsSelf-reported abstinenceRandomized clinical trialsIllicit drugsSubstance use disordersSelf-management systemCognitive behavioral therapyAdjunctive treatmentPrimary outcomeMethadone treatmentSmall trialsClinical trialsEfficacy trialsAbstinence outcomesUse disordersPatient engagementPatientsAn investigation of an open‐access model for scaling up methadone maintenance treatment
Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction 2018, 113: 1450-1458. PMID: 29453891, DOI: 10.1111/add.14198.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderMethadone maintenance treatmentOpioid useMaintenance treatmentTreatment accessUse disordersTreatment modelMethadone maintenance treatment centersMaintenance treatment centersDeleterious effectsMethadone treatmentPatient mortalityTreatment optionsTreatment outcomesTreatment centersProspective patientsRate of retentionPatient censusRapid enrollmentAddiction treatmentApparent deleterious effectsTreatmentMortalityProgrammatic outcomes
2007
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal Of Substance Use And Addiction Treatment 2007, 35: 87-92. PMID: 17933486, PMCID: PMC2587397, DOI: 10.1016/j.jsat.2007.08.004.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNaloxone treatmentHIV risk behaviorsHIV riskRisk behaviorsHuman immunodeficiency virus (HIV) risk behaviorsDrug-related HIV riskHuman immunodeficiency virus (HIV) riskSex-related HIV risk behaviorsBuprenorphine/naloxoneIntravenous drug useOpioid-dependent personsPrimary care clinicsInconsistent condom useBuprenorphine/Care clinicsMethadone treatmentPrimary careDrug useSteady partnerCondom useBaselineWeeksTreatmentPatients